REPORT ID 1982

EMEA (Europe, Middle East and Africa) Breast Cancer Drugs Market Report 2017

Publish Date
7-Dec-17
Pages
107
Format
Electronic (PDF)

In this report, the EMEA Breast Cancer Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Breast Cancer Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Breast Cancer Drugs market competition by top manufacturers/players, with Breast Cancer Drugs sales volume (K MT), price (USD/MT), revenue (Million USD) and market share for each manufacturer/player; the top players including
    GlaxoSmithKline
    Sun Pharmaceutical Industries
    Actavis
    Hospira
    Bayer AG
    Janssen Biotech
    Accord Healthcare
    Gilead Sciences

On the basis of product, this report displays the sales volume (K MT), revenue (Million USD), product price (USD/MT), market share and growth rate of each type, primarily split into
    Chemotherapy
    Surgery & Radiation Therapy
    Targeted Therapy
    Hormonal Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K MT), market share and growth rate of Breast Cancer Drugs for each application, including
    Hospital
    Clinic
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Breast Cancer Drugs Market Report 2017
1 Breast Cancer Drugs Overview
    1.1 Product Overview and Scope of Breast Cancer Drugs
    1.2 Classification of Breast Cancer Drugs
        1.2.1 EMEA Breast Cancer Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Breast Cancer Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Chemotherapy
        1.2.4 Surgery & Radiation Therapy
        1.2.5 Targeted Therapy
        1.2.6 Hormonal Therapy
    1.3 EMEA Breast Cancer Drugs Market by Application/End Users
        1.3.1 EMEA Breast Cancer Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Other
    1.4 EMEA Breast Cancer Drugs Market by Region
        1.4.1 EMEA Breast Cancer Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Breast Cancer Drugs (2012-2022)
        1.5.1 EMEA Breast Cancer Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Breast Cancer Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Breast Cancer Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Breast Cancer Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Breast Cancer Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Breast Cancer Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Breast Cancer Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Breast Cancer Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Breast Cancer Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Breast Cancer Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Breast Cancer Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Breast Cancer Drugs (Volume) by Application
    2.4 EMEA Breast Cancer Drugs (Volume and Value) by Region
        2.4.1 EMEA Breast Cancer Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Breast Cancer Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Breast Cancer Drugs Sales Price by Region (2012-2017)

3 Europe Breast Cancer Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Breast Cancer Drugs Sales and Value (2012-2017)
        3.1.1 Europe Breast Cancer Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Breast Cancer Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Breast Cancer Drugs Sales and Market Share by Type
    3.3 Europe Breast Cancer Drugs Sales and Market Share by Application
    3.4 Europe Breast Cancer Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Breast Cancer Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Breast Cancer Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Breast Cancer Drugs Sales and Growth Rate (2012-2017)

4 Middle East Breast Cancer Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Breast Cancer Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Breast Cancer Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Breast Cancer Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Breast Cancer Drugs Sales and Market Share by Type
    4.3 Middle East Breast Cancer Drugs Sales and Market Share by Application
    4.4 Middle East Breast Cancer Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Breast Cancer Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Breast Cancer Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Breast Cancer Drugs Sales and Growth Rate (2012-2017)

5 Africa Breast Cancer Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Breast Cancer Drugs Sales and Value (2012-2017)
        5.1.1 Africa Breast Cancer Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Breast Cancer Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Breast Cancer Drugs Sales and Market Share by Type
    5.3 Africa Breast Cancer Drugs Sales and Market Share by Application
    5.4 Africa Breast Cancer Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Breast Cancer Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Breast Cancer Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Breast Cancer Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Breast Cancer Drugs Sales and Growth Rate (2012-2017)

6 EMEA Breast Cancer Drugs Manufacturers/Players Profiles and Sales Data
    6.1 GlaxoSmithKline
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Breast Cancer Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 GlaxoSmithKline Breast Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Sun Pharmaceutical Industries
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Breast Cancer Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Sun Pharmaceutical Industries Breast Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Actavis
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Breast Cancer Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Actavis Breast Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Hospira
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Breast Cancer Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Hospira Breast Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Bayer AG
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Breast Cancer Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Bayer AG Breast Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Janssen Biotech
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Breast Cancer Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Janssen Biotech Breast Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Accord Healthcare
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Breast Cancer Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Accord Healthcare Breast Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Gilead Sciences
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Breast Cancer Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Gilead Sciences Breast Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview

7 Breast Cancer Drugs Manufacturing Cost Analysis
    7.1 Breast Cancer Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Breast Cancer Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Breast Cancer Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Breast Cancer Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Breast Cancer Drugs Market Forecast (2017-2022)
    11.1 EMEA Breast Cancer Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Breast Cancer Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Breast Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Breast Cancer Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Breast Cancer Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Breast Cancer Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Breast Cancer Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Breast Cancer Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Breast Cancer Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Breast Cancer Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer